CompletedNot Applicable

Pharmacokinetics of Daunorubicin in Young Patients With Cancer

United States107 participantsStarted 2007-01

Plain-language summary

This laboratory study is looking at the pharmacokinetics of daunorubicin in young patients with cancer. Collecting and storing samples of blood from patients with cancer to study in the laboratory may help doctors learn more about how patients respond to treatment with certain chemotherapy drugs.

Who can participate

Age range21 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

DISEASE CHARACTERISTICS: * Diagnosis of any malignancy * Must be receiving a chemotherapy regimen that includes daunorubicin hydrochloride administered as an infusion of any duration for \< 24 hours on either a 1- or a 2-day schedule, including bolus and all short infusion schedules PATIENT CHARACTERISTICS: * Not pregnant or nursing * No significant uncontrolled systemic illness * Large implanted prostheses allowed (should not undergo dual energy x-ray absorptiometry scan) PRIOR CONCURRENT THERAPY: * See Disease Characteristics

What they're measuring

Population Estimates for Daunorubicin Hydrochloride Clearance

Timeframe: Prior to drug infusion, midpoint, and end of infusion. Also 0.5,1,1.5,2,3,4,6,8 and 12 hours after end of infusion.

Population Estimates for Daunorubicin Hydrochloride Volume of Distribution

Timeframe: Prior to drug infusion, midpoint, and end of infusion. Also 0.5,1,1.5,2,3,4,6,8 and 12 hours after end of infusion.

Trial details

NCT IDNCT00673257

SponsorChildren's Oncology Group

Sponsor typeNETWORK

Study typeINTERVENTIONAL

Primary completion2011-07

Results submitted2013-10-08

View on ClinicalTrials.gov More Unspecified Childhood Solid Tumor, Protocol Specific trials